Child Psychiatry & Human Development, Год журнала: 2019, Номер 50(6), С. 940 - 949
Опубликована: Май 13, 2019
Язык: Английский
Child Psychiatry & Human Development, Год журнала: 2019, Номер 50(6), С. 940 - 949
Опубликована: Май 13, 2019
Язык: Английский
European Archives of Psychiatry and Clinical Neuroscience, Год журнала: 2018, Номер 269(1), С. 107 - 120
Опубликована: Дек. 19, 2018
Язык: Английский
Процитировано
211Journal of Dual Diagnosis, Год журнала: 2019, Номер 16(1), С. 22 - 42
Опубликована: Окт. 24, 2019
Objective: This review discusses the relationship between cannabis use and psychotic, bipolar, depressive, anxiety disorders, as well suicide. It summarizes epidemiological evidence from cross-sectional long-term prospective studies considers possible etiological mechanisms. Methods: Systematic reviews methodologically robust in field (from inception to February 2019) were identified using a comprehensive search of Medline, PsychINFO, Embase summarized narrative synthesis. Results: Consistent evidence, both observational experimental studies, has confirmed important role initiation persistence psychotic disorders. The size effect is related extent use, with greater risk for early high-potency varieties synthetic cannabinoids. Accumulating suggests that frequent also increases mania However, on depression less clear findings are contradictory only few studies. Furthermore, common mental disorders may involve reverse causality, reported lead consumption some Pathogenetic mechanisms focus tetrahydrocannabinol (THC, main psychoactive ingredient cannabis) interacting genetic predisposition perhaps other environmental factors. Cannabidiol (CBD), traditional cannabis, ameliorates psychotogenic effects THC but absent increasingly available. Conclusions: heavy high-THC/low-CBD types psychosis sufficiently strong merit public health education. Evidence similar smaller suicide growing, not convincing anxiety. There much current interest possibility CBD be therapeutically useful.
Язык: Английский
Процитировано
113European Neuropsychopharmacology, Год журнала: 2020, Номер 33, С. 1 - 35
Опубликована: Март 9, 2020
Язык: Английский
Процитировано
110Frontiers in Human Neuroscience, Год журнала: 2020, Номер 14
Опубликована: Авг. 4, 2020
Adolescence is an important ontogenetic period that characterized by behaviors such as enhanced novelty-seeking, impulsivity, and reward preference, which can give rise to increased risk for substance use. While use rates in adolescence are generally on a decline, the current combined with emerging trends, increases e-cigarette use, remain significant public health concern. In this review, we focus neurobiological divergences associated adolescent derived from cross-sectional, retrospective, longitudinal studies, highlight how of these substances during may relate behavioral neuroimaging-based outcomes. Identifying understanding associations between changes cognition, mental health, future assist our consequences drug exposure critical window.
Язык: Английский
Процитировано
99Brain Sciences, Год журнала: 2023, Номер 13(2), С. 325 - 325
Опубликована: Фев. 14, 2023
Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety depression are cited as either primary or secondary reason the use cannabinoids. Aim: The purpose this review to explore association between dysregulation endogenous endocannabinoid system (ECS), well phytocannabinoids synthetic cannabinoids in remediation depression/anxiety symptoms. After brief description constituents cannabis, cannabinoid receptors system, most important evidence presented involvement both human from animal models anxiety. Finally, clinical treat Conclusions: Although common belief that cannabinoids, including its main studied components—tetrahydrocannabinol (THC) cannabidiol (CBD)—or other derivatives have been suggested therapeutic role certain mental health conditions, all recent systematic reviews we report concluded improve depressive disorders weak, very-low-quality, offers no guidance on conditions within regulatory framework. an urgent need high-quality studies examining effects general particular, consequences long-term these due possible risks such addiction even reversal improvement.
Язык: Английский
Процитировано
39American Journal on Addictions, Год журнала: 2019, Номер 29(1), С. 9 - 26
Опубликована: Окт. 2, 2019
Background and Objectives Cannabis use is common in people with mood anxiety disorders (ADs), rates of problematic are higher than the general population. Given recent policy changes favor cannabis legalization, it important to understand how cannabinoids may impact these disorders. We aimed assess effects on onset course depression, bipolar disorder, ADs, post‐traumatic stress disorder (PTSD), also explore therapeutic potential for Methods A systematic review literature was completed. The PubMed® database from January 1990 May 2018 searched. included longitudinal cohort studies, all studies using or a cannabinoid as an active intervention, regardless study design. Results Forty‐seven were included: 32 reported illness onset, nine course, six therapeutics. Cohort varied significantly design quality. suggests that linked poorer clinical PTSD, but this finding not clear depression (ADs). There have been few high‐quality pharmaceuticals settings. Conclusions Scientific Significance These conclusions limited by lack well‐controlled studies. suggest future research be directed toward high‐quality, prospective populations addition controlled constituents populations. (Am J Addict 2019;00:00–00)
Язык: Английский
Процитировано
68Substance Abuse Treatment Prevention and Policy, Год журнала: 2020, Номер 15(1)
Опубликована: Июнь 24, 2020
Abstract Background Young people with substance use problems face a high risk of co-occurring mental health problems, something that may involve more difficult life situation, social as well worse treatment outcomes. The aim this study is to analyse self-reported among young receiving outpatient for in Sweden. We explore what types are or less predominant, and whether there significant differences between boys girls. In addition, we how various covary indicators abuse severity. Methods based on structured interviews 1970 enrolled at clinics 11 Swedish cities. data was analysed through frequency- averages-calculations, Chi-square tests multivariate logistic regression analyses. Results Self-reported were common the study. A relatively large percentage total group (34–54%) reported such concentration difficulties, sleeping anxiety depression. At same time, many did not report any symptoms only small group, about 20%, diagnosed disorders. results show substantial gender differences, girls reporting significantly higher levels problems. Multivariate analyses demonstrated associations severity drug anxiety, aggression, hallucinations stress caused by experiences trauma. Conclusions Treatment needs diverse within who drugs. Since all larger burden psychosocial factors than boys, they likely require comprehensive interventions. link severe points importance exploring relationship treatment. multidisciplinary approach, which can be addressed simultaneously, best form
Язык: Английский
Процитировано
64Current Addiction Reports, Год журнала: 2020, Номер 7(3), С. 344 - 355
Опубликована: Июль 14, 2020
Язык: Английский
Процитировано
62Current Opinion in Psychiatry, Год журнала: 2019, Номер 33(1), С. 20 - 42
Опубликована: Ноя. 12, 2019
This review is to summarize most recent evidence published in the last 18 months on medical and recreational use of cannabis cannabinoids relation anxiety, depression (unipolar bipolar), dysregulation emotions as part posttraumatic stress disorders (PTSD) emotionally instable personality disorders. It also covers investigation endocannabinoids potential biomarkers these conditions. important with increasing medicinal growing social tolerance towards use.There some suggesting cannabinoids, cannabidiol or cannabidiol-enriched preparations have anxiolytic properties. In addition, may be worsened by use, however, randomized controlled trials (RCT) are lacking. New suggests that for PTSD emotion regulation can induce hyporesponse fear stress. Further, several lines point endocannabinoid system a key player reviewed disorders, particular anxiety PTSD.The therapeutic conditions weak lacking well designed RCTs. However, there indication role warrant further studies.
Язык: Английский
Процитировано
57Frontiers in Psychiatry, Год журнала: 2021, Номер 12
Опубликована: Фев. 16, 2021
Background: Cannabis is known to have a broad range of effects on behavior, including experiencing “high” and tranquility/relaxation. However, there are several adverse behavioral sequalae that can arise from cannabis use, depending frequency potency (e.g., THC content), age onset, cumulative exposure. This systematic review examined evidence for cannabis-related in otherwise healthy human subjects. Methods: Following PRISMA guidelines, we conducted cross-sectional longitudinal studies 1990 2020 identified outcomes subjects without psychiatric medical co-morbidities PubMed PsychInfo searches. Key search terms included “cannabis” OR “tetrahydrocannabinol” “cannabidiol” “marijuana” AND “anxiety” “depression” “psychosis” “schizophrenia” “OR “IQ” “memory” “attention” “impulsivity” “cognition” “education” “occupation”. Results: Our detected total 2,870 studies, which extracted 124 relevant the literature non-clinical population. Effects sequelae cognition, motivation, impulsivity, mood, anxiety, psychosis intelligence, psychosocial functioning were identified. The preponderance suggests (but not CBD) content, exposure all contribute these individuals pre-existing condition or disorder. strongest negative functioning. Conclusions: Although more research needed determine risk factors development findings underline importance understanding vulnerability cannabis, has implications prevention treatment problematic use.
Язык: Английский
Процитировано
44